摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(4-bromophenoxy)ethyl]-azepane | 89967-97-5

中文名称
——
中文别名
——
英文名称
1-[2-(4-bromophenoxy)ethyl]-azepane
英文别名
1-[2-(4-Bromophenoxy)ethyl]azepane
1-[2-(4-bromophenoxy)ethyl]-azepane化学式
CAS
89967-97-5
化学式
C14H20BrNO
mdl
MFCD13199336
分子量
298.223
InChiKey
CGBJBRVRGPNBMT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.571
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,8-bis(tert-butyl-dimethyl-silyloxy)-11H-chromeno[4,3-c]chromen-5-one1-[2-(4-bromophenoxy)ethyl]-azepane甲基溴化镁正丁基锂 作用下, 以 四氢呋喃乙醚正己烷 为溶剂, 反应 2.0h, 生成 2-[4-{1-[4-(2-azepan-1-yl-ethoxy)-phenyl]-1-hydroxy-ethyl}-7-(tert-butyl-dimehyl-silyloxy)-2H-chromen-3-yl]-5-(tert-butyl-dimethyl-silyloxy)-phenol
    参考文献:
    名称:
    Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
    摘要:
    本发明涉及包含杂原子的新型四环衍生物,包含它们的药物组合物,它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用,以及它们的制备过程。发明中的化合物在治疗和/或预防与雌激素耗竭相关的疾病中是有用的,如热潮红、阴道干涩、骨量减少和骨质疏松症;激素敏感性癌症和乳腺、子宫内膜、宫颈和前列腺的增生;子宫内膜异位症、子宫肌瘤、骨关节炎,并且作为避孕剂,单独使用或与孕激素或孕激素拮抗剂结合使用。
    公开号:
    US20030216463A1
  • 作为产物:
    描述:
    2-(环己亚氨基)乙基氯 在 sodium hydride 、 sodium iodide 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 0.17h, 生成 1-[2-(4-bromophenoxy)ethyl]-azepane
    参考文献:
    名称:
    Selective estrogen receptor modulators
    摘要:
    公开号:
    EP1577288B1
点击查看最新优质反应信息

文献信息

  • Selective Estrogen Receptor Modulator
    申请人:Hamaoka Shinichi
    公开号:US20120004315A1
    公开(公告)日:2012-01-05
    The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
    本发明提供一种由以下式(I)表示的化合物; [其中T表示单键,可能具有取代基的C1-C4烷基和类似物;式(I-1)表示单键或双键;A表示单键,可能具有取代基的双价5-至14-成员杂环基和类似物;Y表示单键和类似物;Z表示亚甲基基团和类似物;环G表示苯基团和类似物,可能与5-至6-成员环缩合并可能具有杂原子;Ra和Rb相同或不同,表示氢原子和类似物;W表示单键和类似物;R'表示1到4个独立的氢原子和类似物;R''表示1到4个独立的氢原子和类似物]或其盐或水合物。
  • [EN] TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] HETERO-COMPOSES TETRACYCLIQUES UTILISABLES COMME MODULATEURS DU RECEPTEUR DES OESTROGENES
    申请人:ORTHO MCNEIL PHARM INC
    公开号:WO2003053977A1
    公开(公告)日:2003-07-03
    The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    本发明涉及新型含杂原子的四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用以及它们的制备过程。该发明的化合物在治疗和/或预防与雌激素缺乏有关的疾病方面具有用处,例如潮热、阴道干燥、骨质疏松症和骨质疏松症;激素敏感性癌症和乳腺、子宫内膜、子宫颈和前列腺的增生;子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕药物,单独使用或与孕激素或孕激素拮抗剂组合使用。
  • Selective estrogen receptor modulator
    申请人:Hamaoka Shinichi
    公开号:US20060116364A1
    公开(公告)日:2006-06-01
    The present invention provides a compound represented by the following formula [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof
    本发明提供了一种化合物,其表示为以下式子[其中T表示单键,C1-C4的烷基,可能带有取代基等;式(I-1)表示单键或双键;A表示单键,二价的5-至14-成员杂环基团,可能带有取代基等;Y表示单键等;Z表示亚甲基等;环G表示苯基团等,可与5-至6-成员环缩合并且可能具有杂原子;Ra和Rb相同或不同,表示氢原子等;W表示单键等;R'表示1至4个独立的氢原子等;R"表示1至4个独立的氢原子等]或其盐,或其水合物。
  • SELECTIVE ESTROGEN RECEPTOR MODULATOR
    申请人:Hamaoka Shinichi
    公开号:US20090325930A1
    公开(公告)日:2009-12-31
    The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; (I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
    本发明提供了一种由以下式(I)表示的化合物;[其中,T表示单键,C1-C4烷基,可以有取代基等;(I-1)式(I-1)表示单键或双键;A表示单键,双价的5-至14-成员杂环基,可以有取代基等;Y表示单键等;Z表示亚甲基等;环G表示苯基等,可以与5-至6-成员环缩合,可以有杂原子;Ra和Rb相同或不同,表示氢原子等;W表示单键等;R′表示1至4个独立的氢原子等;R″表示1至4个独立的氢原子等]或其盐,或其水合物。
  • Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
    申请人:Janssen Pharmaceutica N.V.
    公开号:US07329654B2
    公开(公告)日:2008-02-12
    The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    本发明涉及新颖的含杂原子的四环衍生物,包含它们的制药组合物,以及它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用和制备过程。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病方面具有用途,如潮热,阴道干燥,骨质疏松症;激素敏感性癌症和乳腺,子宫内膜,宫颈和前列腺的增生;子宫内膜异位症,子宫肌瘤,骨关节炎以及作为避孕剂,单独或与孕激素或孕激素拮抗剂联合使用。
查看更多